NCT07246564
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 14 words
- Enrollment closed, study ongoing
- Secondary endpoints: details revised at 4 of 7 entries
- Site details revised at 12 of 12 sites
- Minor Site details revised at 1 of 12 sitesv12
- Minor Study sites: 11 to 12v11
- Minor Study sites: 9 to 11v10
- Minor Study sites: 8 to 9v9
Show 7 earlier versionsHide 7 earlier versions
- Minor Study sites: 7 to 8v8
- Minor Study sites: 6 to 7v7
- Minor Study sites: 5 to 6v6
- Minor Study sites: 4 to 5v5
- Minor Study sites: 3 to 4v4
- Minor Study sites: 2 to 3v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Start date changed from estimate of Dec 2025 to Dec 1, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Change from Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score in the first Treatment Cycle
Timeframe: Baseline to Day 43 (in first treatment cycle)
Secondary (7)
MG-ADL responder (≥2.0-point improvement from Baseline) at Day 43 in the first Treatment Cycle
Change from Baseline to Day 43 in Myasthenia Gravis-Composite (MG-C) score within first 6 week treatment cycle
Change from Baseline to Day 43 in Quantitative Myasthenia Gravis (QMG) score within first 6-week treatment cycle
Change from Baseline to Day 43 in Myasthenia Gravis (MG) Symptoms Patient Reported Outcome (PRO) 'Muscle Weakness Fatigability' score within first 6-week treatment cycle
Change from Baseline to Day 43 in MG Symptoms PRO 'Physical Fatigue' score within first 6-week treatment cycle
Show 2 moreShow less
Percentage of participants with treatment-emergent adverse events (TEAEs)
Percentage of participants with TEAEs leading to withdrawal of investigational medicinal product (IMP)
Arms and interventions
RozanolixizumabExperimental
Participants will receive 6 dose per cycle of subcutaneous infusion of rozanolixizumab
Drugs: Rozanolixizumab
Sites
12 sites in 1 country